Oxycodone extended release - Egalet

Drug Profile

Oxycodone extended release - Egalet

Alternative Names: AD ER oxycodone; EG-P114; Egalet-002; Opioid 2

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egalet
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 20 Feb 2018 Egalet has patent protection for Guardian™ Technology for oxycodone extended release in USA
  • 20 Dec 2017 Oxycodone extended release - Egalet is available for licensing as of 20 Dec 2017. http://egalet.com/
  • 28 Nov 2017 Positive topline efficacy data from a phase III trial in Pain released by Egalet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top